

NEW as of 2027**New as of 2027:**

1. We have optimized and modernized our layout for easier navigation.
 - Our experts are listed by full name for each EQAS/PT.
 - A new feature is the breakdown into “Rili-BÄK-mandatory” and “non-Rili-BÄK-mandatory” categories; see also page 8.
 - New symbols (NEW, Safety Notice, POCT Label) for quick reference.
2. CMS-approved EQAS/PT are clearly marked.
3. All shipping information is in a separate field.
4. Our separate 2027 price catalog is now available to you on RV-Online.
5. We expanded our index to make it easier to search for a specific EQAS/PT.

EQAS/PT newly added to the Program**Molecular Genetics**

- EQAS/PT 590 Molecular Pathology – PIK3CA and ESR1
- EQAS/PT 670 Molecular Genetics – Factor V-Gene (F5)
- EQAS/PT 671 Molecular Genetics – Factor VII-Gene (F7)
- EQAS/PT 672 Molecular Genetics – Factor VIII-Gene (F8)
- EQAS/PT 673 Molecular Genetics – Factor IX-Gene (F9)
- EQAS/PT 674 Molecular Genetics – Factor X-Gene (F10)
- EQAS/PT 675 Molecular Genetics – Factor XI-Gene (F11)
- EQAS/PT 676 Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)
- EQAS/PT 677 Molecular Genetics – Factor XIII-Gene (F13A1, F13B)
- EQAS/PT 678 Molecular Genetics – von Willebrand Factor-Gene (VWF)
- EQAS/PT 701 Molecular Genetics – FLT3 (internal tandem duplication)
- EQAS/PT 702 Molecular Oncology – PML::RARA qualitative
- EQAS/PT 706 Molecular Genetics – Hereditary Fever Syndroms
- EQAS/PT 726 Molecular Genetics – UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood
- EQAS/PT 728 Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction

Immunology

- EQAS/PT 256 Autoimmune Diseases – Myositis
- EQAS/PT 268 Autoimmune Diseases – Receptor Encephalitis
- EQAS/PT 657 NK-/ and T cell cytotoxicity

Virus Diagnostics

- EQAS/PT 435 Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens

New Parameter for the following EQAS/PT

Immunology

- EQAS/PT 251: Autoimmune Diseases - Connective Tissue Diseases (ANA)
- EQAS/PT 253: Autoimmune Diseases - Hepatic Syndromes
- EQAS/PT 255: Autoimmune Diseases - Connective Tissue Diseases (ENA)
- EQAS/PT 257: Autoimmune Diseases - Vasculitis / Glomerulopathies
- EQAS/PT 259: Autoimmune Diseases - Autoimmune Dermatitis
- EQAS/PT 265: Autoimmune Diseases - Paraneoplastic Neuropathies

Clinical Chemistry

- EQAS/PT 850: Added new parameters: Bictegravir, Cabotegravir, Doravirine, and Ganciclovir
- EQAS/PT 871: Added new parameters: Brivaracetam and Perampanel
- EQAS/PT 875: Added “Cariprazine” parameter

Virus Diagnostics

- EQAS/PT 410: Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)

CMS approved EQAS/PT

We submitted the documentation for conformity approval in accordance with the CLIA amendments for the following EQA/PT schemes: 344, 391, 409, 410, 421, 422, 423, 424, 435, 720. The decision of CMS is expected in autumn and the catalogue will be updated accordingly.